National Institute Of Tuberculosis And Lung Diseases

The National Institute Of Tuberculosis And Lung Diseases investigates how heart health intersects with lung conditions, especially in patients with obesity and sleep‑related breathing disorders. Research aims to improve cardiovascular outcomes by assessing risk factors and testing supportive therapies.

• Evaluation of cardiovascular risk in individuals with chronic lung disease
• Impact of obstructive sleep apnoea on heart function
• Weight‑loss strategies to reduce cardiac strain in overweight patients
• Monitoring of blood pressure and lipid profiles during lung‑focused trials

With 17 investigators and 32 active studies, the Warsaw site integrates cardiology expertise to broaden patient care.

Genetic drivers of lung cancer are a central focus, exploring inherited mutations that influence tumor behavior and treatment response. The institute seeks to personalize therapy based on molecular signatures.

• Molecular profiling of KRAS G12C mutations in non‑small cell lung cancer
• Targeted approaches for EGFR and HER2 altered tumors
• Study of hereditary Alpha‑1 Antitrypsin Deficiency and its lung manifestations
• Exploration of germline variants that affect drug metabolism

The research program leverages advanced genomic tools to match patients with the most effective targeted agents.

Autoimmune and eosinophilic disorders affecting the lungs are being examined alongside immunotherapy for cancer, aiming to balance immune activation with safety.

• Novel biologics for Eosinophilic Granulomatosis with Polyangiitis
• Immune modulation in autoimmune pulmonary alveolar proteinosis
• Combination checkpoint inhibition for advanced lung cancer
• Biomarker‑guided strategies to predict immune‑related adverse events

These studies aim to broaden therapeutic options for patients whose immune systems drive disease progression.

A robust portfolio addresses a spectrum of lung cancers, from early‑stage resected tumors to aggressive small‑cell disease, testing new agents and combination regimens to extend survival.

• Targeted and immunotherapy combinations for advanced non‑small cell lung cancer
• First‑line strategies for extensive‑stage small cell lung cancer
• Adjuvant treatments after surgical removal of early‑stage tumors
• Evaluation of novel KRAS inhibitors in metastatic disease

The site’s multidisciplinary team collaborates to bring innovative cancer therapies to patients across disease stages.

Overweight, obesity, and sleep‑related breathing disorders are examined for their role in lung health, with interventions designed to improve metabolic balance and quality of life.

• Weight‑reduction programs for patients with chronic respiratory disease
• Assessment of obstructive sleep apnoea treatment impact on metabolic markers
• Integrated lifestyle counseling alongside lung‑focused therapies
• Monitoring of body‑mass index and metabolic panels during trials

By addressing metabolic factors, the institute seeks to enhance overall treatment efficacy and patient wellbeing.

The core mission revolves around progressive lung disorders, including fibrosis, emphysema, and rare deficiency states, with a focus on slowing disease progression and improving lung function.

• Antifibrotic agents for idiopathic pulmonary fibrosis and progressive fibrosing ILDs
• Replacement therapy trials for Alpha‑1 Antitrypsin Deficiency‑related emphysema
• Novel inhaled treatments targeting lung tissue preservation
• Long‑term safety studies of emerging therapies in chronic interstitial lung disease

With a dedicated team of 17 investigators, the Warsaw clinic remains a leading center for respiratory research in Europe.